PWM
ALXN

Perigon Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Perigon Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,349
Closed -$248K – 565
2021
Q2 		$248K Buy
+1,349
New +$232K 0.02% 451
2021
Q1 		– Sell
-614
Closed -$96K – 1103
2020
Q4 		$96K Buy
+614
New +$78.9K 0.01% 550
2017
Q2 		– Sell
-55
Closed -$7K – 637
2017
Q1 		$7K Buy
55
+18
+49% +$2.32K ﹤0.01% 558
2016
Q4 		$5K Buy
+37
New +$4.53K ﹤0.01% 651

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Perigon Wealth Management's ALXN Position: Q3 2021 in Review

Perigon Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,349 shares — an estimated $248K sold.

Perigon Wealth Management first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $248K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Perigon Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 1,349 Alexion Pharmaceuticals shares in Q3 2021, an estimated $248K.
  • Perigon Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Perigon Wealth Management's Alexion Pharmaceuticals position peaked at $248K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Perigon Wealth Management's 13F filing for Q3 2021, filed 25 Oct 2021.